Minze Health has reached an agreement with Medtronic for three years to market the automated bladder diary solution, Minze Diary Pod, across the Europe, Middle East, and Africa (EMEA) region.
This partnership aims to broaden the range of support services available to individuals experiencing bladder control issues, referred to as overactive bladder (OAB), particularly those receiving sacral neuromodulation (SNM) therapy using Medtronic’s InterStim system.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
As part of this collaboration, the Minze Diary Pod will be incorporated into the SNM care pathway.
The device enables both individuals and clinicians to collect data throughout the diagnosis and follow-up phases.
This integration is intended to assist in making timely decisions regarding the initiation of SNM therapy and to offer insights into the effectiveness of the treatment following implantation.
Individuals can monitor their urinary behaviour at home with the help of the Minze Diary Pod without relying on paper records.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataHealthcare providers can also gain from automated data interpretation and a secure digital platform for remote oversight and clinical assessment.
Minze Health specialises in digital diagnostics and therapeutics in urology. The company’s technology, which holds CE mark and 510(k) exemptions, is designed to support early diagnosis and personalised care for conditions such as benign prostatic hyperplasia (BPH) and OAB.
Minze Health CEO Thomas Moore said: “We’re proud to collaborate with Medtronic to bring our technology to more patients and providers across Europe and beyond.
“Together, we’re transforming the way urological symptoms are assessed, treated and monitored — with digital tools that enable precision, efficiency and patient engagement.”
In October 2024, Minze Health raised $5.3m in a funding round. The proceeds were aimed at advancing prescription digital therapeutic solutions for those with urinary dysfunctions, with initial plans focusing on France and Germany, and supporting entry into the US market with Minze’s home diagnostics offerings.
